Levodopa/Carbidopa/Entacapone Orion

Levodopa, the active ingredient in Levodopa/Carbidopa/Entacapone Orion, is a Levodopa/carbidopa/entacapone combination presented as an oral tablet for oral use. It works to replenish central dopamine levels and is indicated for the treatment of Parkinson's disease motor fluctuations in adult patients.

GNH USA supplies Levodopa/Carbidopa/Entacapone Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets. The company adheres to WHO GMP guidelines and provides reliable logistics for timely delivery.

Levodopa/Carbidopa/Entacapone is indicated for Parkinson's disease, targeting motor symptom control and fluctuation management.

- Parkinson's disease (early stage): improves rigidity, bradykinesia, tremor and overall motor performance, allowing better daily activity. - Parkinson's disease (advanced stage): reduces off‑time, smooths motor fluctuations and enhances overall motor function, supporting independence in complex tasks. - Parkinson's disease with wearing‑off phenomenon: provides more stable dopamine levels, lessens symptom variability and helps maintain consistent motor control throughout the day. - Parkinson's disease (adjunct therapy): used together with other antiparkinson agents to optimize levodopa response and improve overall symptom control.

Levodopa/Carbidopa/Entacapone may cause a range of adverse reactions, which are classified by frequency.

Common Side Effects: - Nausea: upset stomach feeling - Vomiting: expulsion of stomach contents - Dizziness or light‑headedness: sensation of imbalance - Orthostatic hypotension: drop in blood pressure upon standing - Headache: mild to moderate head pain - Insomnia: difficulty falling or staying asleep

Serious or Rare Side Effects: - Dyskinesia: involuntary, erratic movements - Hallucinations or psychosis: visual or auditory disturbances - Severe hypotension or syncope: marked blood pressure drop leading to fainting - Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity - Severe allergic reactions: rash, angioedema, or anaphylaxis - Depression or suicidal thoughts: mood changes requiring immediate medical attention

When prescribing Levodopa/Carbidopa/Entacapone, clinicians should observe several precautionary measures to ensure safe use.

- Dose adjustment: titrate according to clinical response and tolerability. - Renal impairment: monitor kidney function and adjust dose if necessary. - Hepatic impairment: use with caution and assess liver enzymes regularly. - Concomitant MAO‑B inhibitors: avoid due to risk of hypertensive crisis. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at room temperature: keep in original container, protect from moisture and light.

Levodopa/Carbidopa/Entacapone can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: concurrent use may precipitate a hypertensive crisis due to excess catecholamines. - Antipsychotics (e.g., haloperidol, risperidone): can antagonize dopamine receptors and reduce therapeutic efficacy. - Antihypertensives: combined effect may cause excessive blood pressure reduction and fainting.

Moderate Interactions (Monitor Closely): - SSRIs or SNRIs: may increase serotonin levels and raise the risk of serotonin syndrome. - Iron or calcium supplements: can bind levodopa in the gut, decreasing its absorption if taken together. - High‑protein meals: compete with levodopa for intestinal transport, potentially diminishing its clinical effect.